The MORL uses genetic and functional studies of the complement cascade to study the pathogenesis of ultra-rare complement-mediated renal diseases and to identify therapeutic targets to mitigate renal damage.

My laboratory is studying the pathophysiology of complement-mediated renal diseases like C3 Glomerulopathy and atypical hemolytic uremic syndrome.